Horizon Pharma (HZNP) shares plunged Thursday after the biopharmaceutical company reported that its neuromuscular disorder treatment failed late-stage trials. The drug has already been approved by the U.S. Food and Drug Administration for use in two other rare genetic conditions. The company says today's announcement does not affect its full year 2016 adjusted net sales, though the company has previously said that it expects its rare disease treatments to account for about 60% of its net sales by 2020.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.